Loading…
Vistagen Therapeutics, Inc. is projected to rise to $0.7717 by 2027, a +24% move from its current price of $0.6241. VTGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.6049 | $0.6245 | $0.6447 | +0.06% |
| May 30 | $0.5973 | $0.6248 | $0.6536 | +0.12% |
| May 31 | $0.5916 | $0.6252 | $0.6607 | +0.18% |
| Jun 1 | $0.5869 | $0.6256 | $0.6667 | +0.23% |
| Jun 2 | $0.5829 | $0.6259 | $0.6721 | +0.29% |
| Jun 3 | $0.5793 | $0.6263 | $0.6771 | +0.35% |
| Jun 4 | $0.576 | $0.6267 | $0.6818 | +0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.576 | $0.6267 | $0.6818 | +0.41% |
| Week 2 | $0.5585 | $0.6292 | $0.7089 | +0.82% |
| Week 3 | $0.546 | $0.6318 | $0.7311 | +1.23% |
| Week 4 | $0.536 | $0.6344 | $0.7509 | +1.65% |
| Week 5 | $0.5276 | $0.637 | $0.7691 | +2.06% |
| Week 6 | $0.5203 | $0.6396 | $0.7863 | +2.48% |
| Week 7 | $0.5138 | $0.6422 | $0.8027 | +2.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company in Healthcare that develops therapies for neuropsychiatric and neurological disorders. Its product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder.
It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase II clinical trial for the treatment to improve cognitive impairment caused by mental fatigue and potentially other disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial to treat loss of appetite associated with chronic disorders, such as cancer or heart disease, as well as cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. In addition, the company's clinical-stage pipeline consists of intranasal product candidates comprising pherines. It has a license and collaboration agreement with AffaMed Therapeutics, Inc.
to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
Vistagen Therapeutics, Inc. (VTGN) is a healthcare stock with a clinical-stage biopharmaceutical focus. The current price is $0.647 and the market capitalization is $25.63M, with a market ranking of 4873.
The stock's price outlook appears biased to the upside over the extended horizon, supported by a multi-year forecast that projects rising averages from 2026 through 2050 and sizable potential upside in later years. The pipeline and partnership with AffaMed position the company within a clinical development framework, though outcomes remain uncertain given the early-stage nature of its programs.
A major floor 18.3% below — a decisive break under it would weaken the trend.
The nearest floor, 8.7% below — buyers have tended to step in here.
The nearest ceiling, 7.4% above — a clean break opens room to run.
A major ceiling 15.4% above — clearing it would confirm fresh momentum.
Key VTGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.638 | Sell | $0.6328 | Sell |
| MA 10 | $0.635 | Sell | $0.6317 | Sell |
| MA 20 | $0.6255 | Sell | $0.6248 | Sell |
| MA 50 | $0.6054 | Buy | $0.6557 | Sell |
| MA 100 | $0.6072 | Buy | $0.96 | Sell |
| MA 200 | $2.05 | Sell | $1.55 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.71 | Neutral |
| Stoch RSI (14) | 14.57 | Buy |
| CCI (20) | -20.31 | Neutral |
| Williams %R (14) | -62.50 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 1.64 | Buy |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 37.50 | Neutral |
| TRIX (15) | 0.24 | Buy |
| Awesome (5,34) | 0.03 | Buy |
| Ultimate (7,14,28) | 50.69 | Neutral |
| Momentum (10) | 0.00 | Neutral |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 0.64 | Sell |
| ADX (14) | 7.99 | Neutral |
| ATR (14) | 0.02 | Info |
In the near term, the technical picture reads as BULLISH, with RSI(14) at 60. The 50-day simple moving average sits at $0.605 and the 200-day simple moving average at $2.07, indicating a broader gap to the longer-term trend. Support is at $0.57 and resistance at $0.67, framing a narrow near-term range with the 30-day range between $0.5202 and $0.8047.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.51 | $0.6241 | $0.8525 | 0% | Neutral | |
| $0.6022 | $0.7717 | $1.05 | +24% | Bullish | |
| $0.7521 | $0.9955 | $1.42 | +60% | Bullish | |
| $0.7834 | $1.07 | $1.56 | +71% | Bullish | |
| $0.8023 | $1.12 | $1.69 | +79% | Bullish | |
| $0.8493 | $1.21 | $1.87 | +94% | Bullish | |
| $0.7948 | $1.16 | $1.82 | +85% | Bullish | |
| $0.857 | $1.27 | $2.04 | +104% | Bullish | |
| $1.02 | $1.55 | $2.53 | +148% | Bullish | |
| $1.13 | $1.74 | $2.89 | +179% | Bullish | |
| $1.33 | $2.23 | $3.96 | +257% | Bullish | |
| $2.26 | $4.37 | $8.60 | +601% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.51 | $0.6241 | $0.7382 | +0.00% |
| June 2026 | $0.5599 | $0.6599 | $0.7981 | +5.74% |
| July 2026 | $0.553 | $0.6582 | $0.8085 | -0.26% |
| August 2026 | $0.5322 | $0.6384 | $0.7936 | -3.01% |
| September 2026 | $0.5421 | $0.6544 | $0.8214 | +2.50% |
| October 2026 | $0.5546 | $0.6735 | $0.8528 | +2.91% |
| November 2026 | $0.54 | $0.6592 | $0.8412 | -2.11% |
| December 2026 | $0.5407 | $0.6633 | $0.8525 | +0.62% |
Click any year to see its month-by-month VTGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VTGN to range from $0.51 to $0.8525 through 2026. The $0.6241 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The VTGN price prediction for 2027 points to an average of $0.7717 (low $0.6022, high $1.05) — a potential gain of +24% on today's $0.6241. Buyers look set to stay in control over this stretch.
In 2028, VTGN is projected to trade between $0.7521 and $1.42, averaging $0.9955 — a potential gain of +60% from today's $0.6241. That is up +29% on the projected 2027 average. Momentum favours further upside here.
Vistagen Therapeutics, Inc.'s 2029 outlook centres on $1.07, within a $0.7834 to $1.56 range. That is up +7% on the projected 2028 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, VTGN could reach as high as $1.69, with a base case around $1.12 and support toward $0.8023 — roughly +79% from $0.6241. Momentum favours further upside here.
Expect VTGN to range from $0.8493 to $1.87 through 2031. The $1.21 average target implies a +94% move from current prices. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The VTGN price prediction for 2032 points to an average of $1.16 (low $0.7948, high $1.82) — a potential gain of +85% on today's $0.6241. Momentum favours further upside here.
In 2033, VTGN is projected to trade between $0.857 and $2.04, averaging $1.27 — a potential gain of +104% from today's $0.6241. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Vistagen Therapeutics, Inc.'s 2034 outlook centres on $1.55, within a $1.02 to $2.53 range. That is up +22% on the projected 2033 average. That marks a +148% change versus current levels. Momentum favours further upside here.
By 2035, VTGN could reach as high as $2.89, with a base case around $1.74 and support toward $1.13 — roughly +179% from $0.6241. Buyers look set to stay in control over this stretch.
Expect VTGN to range from $1.33 to $3.96 through 2040. The $2.23 average target implies a +257% move from current prices. That is up +28% on the projected 2035 average. Momentum favours further upside here.
The VTGN price prediction for 2050 points to an average of $4.37 (low $2.26, high $8.60) — a potential gain of +601% on today's $0.6241. Buyers look set to stay in control over this stretch.
Investing $1,000 in VTGN today (≈ 1,602.307323 VTGN) could be worth
$7,008.94
+$6,008.94 (+601%) by 2050 · US Dollar
Based on the average projected VTGN price of $4.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTGNwould be worth at today's price.
$1,000 invested in VTGN on May 27, 2025 (≈ 411.522622 VTGN) would be worth
$256.83
-$743.17 (-74.3%) today · 0.26× · US Dollar
Based on a VTGN entry price of $2.43 vs. today's $0.6241.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.64 | $975.16 | -2.5% |
| 1 month ago | $0.57 | $1,094.91 | +9.5% |
| 3 months ago | $0.61 | $1,023.11 | +2.3% |
| 6 months ago | $4.9 | $127.37 | -87.3% |
| 1 year ago | $2.43 | $256.83 | -74.3% |
| All time (5.0y) ago | $78 | $8 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTGN forecast.
Our base-case forecast reaches $1.20 around 2031.
Implied market cap at $1.20: $47.54M
The multi-year forecast shows substantial upside potential. In 2026 the average price is $0.647 with a projected max of $0.8976 and a min of $0.51, and ROI of 0. The trajectory improves each year: 2027 average $0.8129, max $1.12, min $0.6311 with ROI 25.6 and bullish sentiment, 2030 average $1.18 with max $1.80, min $0.8396 and ROI 82.4, and bullish sentiment.
By 2040 the average is $2.36 with a max of $4.26 and ROI 264.5, remaining bullish, and by 2050 the average reaches $4.70 with a max of $9.38 and ROI 626.2, also bullish. The forecast implies a continued bullish stance from 2027 through 2050, with upside potential acknowledged as estimates rather than guarantees. Key years cited for context include 2030 (avg $1.18, ROI 82.4), 2040 (avg $2.36, ROI 264.5), and 2050 (avg $4.70, ROI 626.2).
Tap a question to reveal the answer.
2030 avg $1.18; min $0.8396; max $1.80; ROI 82.4; sentiment BULLISH.
Forecast shows bullish sentiment from 2027 onward with averages rising to $4.70 by 2050 and ROI up to 626.2, though 2026 is neutral. These are estimates and not guarantees.
Yes—2035 max $3.13 indicates the potential to exceed $3 in the mid-2030s (2035: avg $1.86, max $3.13; 2034 max $2.71).
Current price is $0.647 and market cap is $25.63M.
2026 is neutral, while 2027 through 2050 are bullish.
Vistagen Therapeutics, Inc. Community Discussion
0Share your Vistagen Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.